![if !IE]> <![endif]>
Arrhythmias, Pacemakers, and Internal Cardioverter-Defibrillator Management
Electrolyte disorders, heart structure defects, inflam-mation, myocardial ischemia, cardiomyopathies, and conduction abnormalities can all contribute to the development of perioperative arrhythmias and heart block. Consequently, the anesthesia staff must be prepared to manage both chronic and new-onset cardiac rhythm problems.Supraventricular tachycardias (SVTs) can have hemodynamic consequences secondary to loss of AV synchrony and decreased diastolic filling time.
Loss of the “P” wave on the ECG with a fast ven-tricular response is consistent with SVTs. Most SVTs occur secondary to a reentrant mechanism. Reentrant arrhythmias occur when conduction tis-sues in the heart depolarize or repolarize at varying rates. In this manner, a self-perpetuating loop of repolarization and depolarization can occur in the conduction pathways and/or AV node. SVTs pro-ducing hemodynamic collapse are treated perioper-atively with synchronized cardioversion. Adenosine can likewise be given to slow AV node conduction and potentially disrupt the reentrant loop. SVTs
in patients without accessory conduction bundles (Wolff–Parkinson–White [WPW] syndrome) are treated with β-blockers and calcium channel block-ers. In patients with known WPW, procainamide or amiodarone can be used to treat SVTs. At times, SVTs manifest with a broad QRS complex and seem to be similar to VTs. Such rhythms, when they present, should be treated like VT, until proven otherwise.
Atrial fibrillation (AF) can complicate the peri-operative period (Figure 21–4) Up to 35% of car-diac surgery patients develop postoperative AF. Moreover, many patients present with AF for anes-thesia and noncardiac surgery. The ACC/AHA has issued voluminous guidelines for the outpatient management of AF. The guidelines recommend use of β-blockers or nondihydropyridine calcium antag-onists for ventricular rate control in patients without accessory conduction pathways. Amiodarone, pro-cainamide, disopyramide, and ibutilide are sug-gested for ventricular rate control in patients with accessory pathways. The use of digitalis and nondi-hyropryidine calcium channel blockers is contrain-dicated in patients with accessory pathways.
The ACC/AHA guidelines also recommend anti-thrombotic therapy in patients with long-standing AF. Consequently, many patients with AF will pres-ent to the operating room on some form of anti-thrombotic therapy—often the vitamin K antagonist warfarin. However, ACC/AHA guidelines suggest that aspirin can be an alternative to vitamin K antag-onists in low-risk patients or those with contraindi-cations to oral anticoagulation. Likewise, in patients with AF without mechanical prosthetic heart valves, the guidelines suggest that it is acceptable to discon-tinue anticoagulation for up to 1 week in advance of surgical procedures, without instituting heparin anticoagulation.When AF develops perioperatively, rate control with β-blockers can often be instituted. Chemical cardioversion can be attempted with amiodarone or procainamide. Of note, if the duration of AF is greater than 48 hours, or unknown, ACC/AHA guidelines recommend anticoagulation for 3 weeks prior to and 4 weeks following either electrical or chemical cardioversion. Alternatively, TEE can be performed to rule out the presence of left atrial or left atrial appendage thrombus.
Should AF develop postoperatively, ventricu-lar rate response can be controlled with AV nodal blocking agents, unless contraindicated. Should AF result in hemodynamic instability, synchronized cardioversion can be attempted. Patients at high risk of AF following cardiac surgery can be treated with prophylactic amiodarone.
AF is most frequently associated with loss of atrial muscle and the development of fibrosis. Fibrosis may contribute to reentrant mechanisms of AF as depolarization/repolarization becomes nonhomogeneous. AF may also develop from a focal source often located in the pulmonary veins. In patients with an accessory bundle, AF can pro-duce rapid ventricular responses and hemody-namic collapse. Drugs that slow conduction across the AV node (eg, digitalis, verapamil, diltiazem) do not slow conduction across the accessory pathway, potentially leading to hemodynamic collapse. The ACC/AHA guidelines likewise recommend cau-tion in the use of β-blockers for AF in patients with preexcitation syndromes.
Ventricular arrhythmias have been the sub-ject of much review by the AHA ( Table 21–11). Ventricular premature contractions (VPCs) can appear perioperatively secondary to electrolyte abnormalities (hypokalemia, hypomagnesium, hypocalcemia), acidosis, ischemia, embolic phe-nomenon, mechanical irritation of the heart from central lines, cardiac manipulation, and drug effects. Correction of the underlying source of any arrhythmia should be addressed. Patients can likewise present with VPCs secondary to vari-ous cardiomyopathies (dilated, hypertrophic, and arrhythmogenic right ventricular).
The incidence of sudden cardiac death (SCD) is estimated at 1-2/1000 per year. Consequently, some patients will experience an unexpected death in the perioperative period. All anesthesia providers must be prepared to resuscitate and manage patients with ventricular arrhythmias, including VT (non-sustained and sustained) and ventricular fibrillation.
Nonsustained ventricular tachycardia is a short run of ventricular ectopy that lasts <30 sec and spon-taneously terminates, whereas sustained VT persists longer than 30 seconds. VT is either monomorphic or polymorphic, depending on the QRS complex. If the QRS complex morphology changes, it is desig-nated as polymorphic VT. Torsades de pointes is a form of VT associated with a prolonged QT inter-val, producing a sine wave-like VT pattern on the ECG. Ventricular fibrillation requires immediate resuscitative efforts and defibrillation.
Patients presenting with ventricular ectopy and nonsustained runs of VT should undergo investiga-tion prior to surgery. Supraventricular and ventricu-lar arrhythmias constitute active cardiac conditions that warrant evaluation and treatment prior to elec-tive, noncardiac surgery. Exercise testing, echo-cardiography, and nuclear perfusion studies are all recommended by the ACC/AHA in patients with ventricular arrhythmias as part of their workup and management. Electrophysiologic studies are undertaken to determine the possibility for catheter-mediated ablation of ventricular tachycardias.
Should VT present perioperatively, cardiover-sion is recommended at any point where hemody-namic compromise occurs. Otherwise, treatment with amiodarone or procainamide can be attempted. At all times, therapy should also be directed at iden-tifying any causative sources of the arrhythmia. β-Blockers are useful in the treatment of VT, espe-cially if ischemia is a suspected causative factor in the development of rhythm. The use of β-blockers following myocardial infarction has reduced the incidence of post-MI ventricular fibrillation.
Torsades de pointes is associated with condi-tions that lengthen the QT interval. If the arrhyth-mia develops in association with pauses, pacing can be effective. Likewise, some patients may benefit from isoproterenol infusions, if they develop pause-dependent torsades de pointes. Magnesium sulfate may be useful in patients with long QT syndrome and episodes of torsades.
The development of perioperative ventricular fibrillation (VF) requires defibrillation and the use of resuscitation algorithms. Amiodarone can be used to stabilize the rhythm following successful defibrillation.Following VF, patients can present to sur-gery for both ICD placement and other surgical procedures. ICDs are recommended in patients with a history of survived sudden cardiac death (SCD), decreased ventricular function following
MI, and left ventricular ejection fractions <35%. Additionally, ICDs are used to treat potential sud-den cardiac death in patients with dilated, hypertro-phic, arrhythmogenic right ventricular, and genetic cardiomyopathies.
ICDs usually have a biventricular pacing func-tion that improves the effectiveness of left ventricu-lar contraction. Patients with heart failure frequently have a widened QRS complex >120 msec. In such patients, ventricular systole is less efficient, as the lateral and septal left ventricular walls do not effec-tively contract because of the conduction delay. Cardiac resynchronizaton therapy (CRT) has been shown to improve functional status in patients with heart failure (Table 21–12).
Anesthetic management for the placement of ICDs and other electrophysiologic procedures (eg, catheter ablation) depends on the patient’s under-lying conditions. Many patients present with sys-tolic and diastolic heart failure, and, as such, are dependent on sympathetic tone to maintain blood pressure. Many patients tolerate ICD placement using deep sedation rather than general anesthesia. However, catheter-based electrophysiologic stud-ies can be quite time consuming, and patients can develop atelectasis and airway obstruction. Should the patient’s blood pressure suddenly decline during electrophysiololgic studies, development of peri-cardial tamponade should be ruled out. Emergent drainage of tamponade may be necessary.
Many patients present to surgery with ICDs in place. Published guidelines of the American Society of Anesthesiologists can provide assistance in the management of such patients.
Management is a three-step process, as follows:
· Preoperative. Identify the type of device anddetermine if it is used for antibradycardia functions. Consult with the patient’s cardiologist preoperatively as to the device’s function and use history.
· Intraoperative. Determine whatelectromagnetic interference is likely to present intraoperatively and advise the use of bipolar electrocautery where possible. Assure the availability of temporary pacing and defibrillation equipment and apply pads as necessary. Patients who are pacer dependent can be programmed to an asynchronous mode to mitigate electrical interference. Magnet application to ICDs may disable the antitachycardia function, but not convert to an asynchronous pacemaker. Consultation with the patient’s cardiologist and interrogation of the device is advised.
· Postoperative. The device must be interrogatedto ensure that therapeutic functions have been restored. Patients should be continuously monitored until the antitachycardia functions of the device are restored and its function has been confirmed.
ICDs are particularly problematic intraop-eratively when electrocautery is used because the device may (1) interpret cautery as ventricular fibril-lation; (2) inhibit pacemaker function due to cautery artifact; (3) increase the pacing rate due to activation of a rate-responsive sensor; or (4) temporarily or permanently reset to a backup or reset mode. Use of bipolar cautery, placement of the grounding pad far from the ICD device, and limiting use of the cautery to only short bursts help to reduce the likelihood of problems, but will not eliminate them.
ICD devices should have the defibrillator func-tion programmed off immediately before surgery and reprogrammed back on immediately afterward. External defibrillation pads should be applied and attached to a defibrillator machine intraoperatively.
Careful monitoring of the arterial pulse with pulse oximetry or an arterial waveform is necessary to ensure that the pacemaker is not inhibited and that there is arterial perfusion during episodes of ECG artifact from surgical cautery. The manufacturer should be contacted to determine the best method for managing the device (eg, reprogramming or applying a magnet) prior to surgery. A large num-ber of ICD models are in use; however, most sus-pend their antitachycardia function in response to a magnet.
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.